CAC
ICPT

Cowen and Company’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Cowen and Company’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-57,300
Closed -$13K – 759
2022
Q3 		$13K Buy
+57,300
New +$923K ﹤0.01% 398
2020
Q1 		– Sell
-5,909
Closed -$732K – 555
2019
Q4 		$732K Buy
+5,909
New +$529K 0.06% 113

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Cowen and Company's ICPT Position: Q4 2022 in Review

Cowen and Company sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 57,300 shares — an estimated $13K sold.

Cowen and Company first reported a position in ICPT in Q4 2019 and held it in 2 quarters. The position peaked at $732K in Q4 2019. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • Cowen and Company reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Cowen and Company sold 57,300 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $13K.
  • Cowen and Company first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • Cowen and Company's Intercept Pharmaceuticals, Inc. position peaked at $732K in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.